Latest news about 2024 Saxenda lawsuit: Liraglutide has been approved since 2010 for use in the treatment of diabetes under the brand name Victoza. Victoza has already been tagged as a potential cause of pancreatic cancer. According to reports published by the FDA, Victoza was a suspected cause of more than 300 deaths and over 3,000 hospital visits between 2010 and 2014. Around one-third of those fatalities were the result of pancreatic cancer. Hundreds of Victoza lawsuits have already been filed. It makes sense Victoza would go first because it is an older drug. But, if you believe the science that plaintiffs’ lawyers tried to adopt, Saxenda could cause a greater cancer risk because it contains a much higher dose of Liraglutide than Victoza. This drove interest in Saxenda cancer lawsuits. But conclusive scientific proof did not follow. Discover additional info on Saxenda lawsuit.
Gastroparesis is a condition that affects the normal movement of the muscles in the stomach, causing delayed emptying of the stomach’s contents. It can lead to symptoms such as nausea, vomiting, bloating, and abdominal pain. While various factors can contribute to the development of gastroparesis, recent studies have suggested a potential link between the use of Saxenda and gastroparesis and there has been an increase in the number of reports of individuals who developed gastroparesis after taking Saxenda.
The FDA said it has received reports through its adverse events tracking system of people on the drugs experiencing stomach paralysis that sometimes has not resolved by the time it is reported. Additionally, the American Society of Anesthesiologists warned that patients should stop GLP-1 agonists a week before surgery due to the increased risk that individuals will regurgitate food during surgery, even if they have fasted as directed. If someone vomits under anesthesia it can sometimes cause food and acid in the stomach to make their way into the lungs, possibly causing pneumonia and other similar problems after an operation.
A resident of Kentucky has initiated a lawsuit against Novo Nordisk A/S and its subsidiaries, accusing the company of failing to warn about the potential risk of permanent stomach paralysis caused by its weight loss medication, Saxenda (liraglutide). The plaintiff consumed Saxenda from March 2019 to April 2021 and is now experiencing gastroparesis, which has resulted in severe consequences such as persistent vomiting and abdominal pain, requiring multiple visits to the hospital. The lawsuit alleges that since the drug’s approval by the FDA in 2014, Novo Nordisk has promoted Saxenda as a weight loss solution without adequately disclosing the potential for gastrointestinal disorders, despite clinical trials indicating such risks.
For the individuals taking liraglutide, it took 70 minutes for half their food to leave their stomachs. In contrast, it took only four minutes in the control group, an extreme diversity in the slow-down in digestion. Additionally, for some participants taking liraglutide, it took up to two hours and 30 minutes for half the meal to leave their stomachs. It is important to note that not all individuals who take Saxenda will develop gastroparesis. The link between Saxenda and gastroparesis is still being studied, and further research is needed to determine the extent of this association.
Another one of the serious side effects of Saxenda is kidney damage or kidney failure. As noted herein, Saxenda belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing insulin production and reducing glucose production in the liver. While Saxenda is generally well-tolerated, there have been reports of kidney-related side effects of Saxenda in some individuals. It has been reported that kidney damage appears to happen in people experiencing Saxenda side effects including severe nausea, vomiting, and diarrhea from Saxenda . The belief is that the side effects of Saxenda can result in dehydration, which can lead to kidney damage or worsen existing kidney problems.
Moreover, healthcare professionals have reported an increase in the number of patients presenting with severe gastrointestinal issues, such as persistent vomiting, after starting Saxenda or similar GLP-1 agonist medications. These reports have raised significant concerns about the potential for Saxenda to contribute to the development of gastroparesis and other debilitating Saxenda side effects. Intestinal blockages have been reported by certain individuals who have taken Saxenda (liraglutide). These blockages can hinder the movement of food and waste through the intestines, leading to intense discomfort, swelling, and vomiting. It appears that this one of the Saxenda side effects is more prevalent in males and in those who have been using the medication for a shorter duration. In 2017, eight cases were documented, with the majority of them requiring surgical intervention. Nevertheless, the specific process by which Saxenda induces these blockages is still not fully understood.
While the evidence is still inconclusive, some studies have suggested a potential link between the use of Saxenda and an increased risk of thyroid cancer. Furthermore, in rare cases, individuals taking Saxenda may experience severe allergic reactions, which can be life-threatening if not treated promptly.
If you took Saxenda and developed gallbladder disease, Saxenda stomach paralysis, or any other serious Saxenda side effects, contact Timothy L. Miles, a Sazenda lawyer in Nashville, today. ?You may be eligible for a Saxenda Lawsuit ?and possibly may be entitled to substantial compensation. Find even more info at https://www.masstortsheadquarters.com/saxenda-lawsuit.html/.
?Timothy L. Miles is a plaintiff’s lawyer in Nashville, Tennessee, and a nationally known top-rated class action and product liability lawyer who has been leading the fight to protect the rights of injured victims for over 20 years.
Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for injured victims, consumers, and shareholders, shaped precedent-setting decisions, and delivered real reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards.